Galecto Inc (GLTO)

$3.75 -0.05 (-1.37%)
Market Cap 4.96M
Revenue (ttm) 0.00
Net Income (ttm) -21.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,300
Avg Vol 48,256
Day's Range N/A - N/A
Shares Out 1.32M
Stochastic %K 51%
Beta 1.35
Analysts Hold
Price Target $6.00

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 70 52 10
Website: galecto.com
Address:
Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark
MadMusk
MadMusk Jul. 25 at 9:37 AM
$OKLO I got 1000€ on the Short Side . Now can Oberlap loses on $OPTT . $GLTO
0 · Reply
Investor1337
Investor1337 Jul. 21 at 4:17 PM
$GLTO Realistic timeframe for topline results is Q3–Q4 2025, likely aligned with the major oncology conferences Next: BO / partner / RS? (as an investor I would like ceo to be more in contact with investors)
0 · Reply
signaljumper
signaljumper Jul. 14 at 9:55 PM
$GLTO teady for 4$++ If we get some more volume than stocj could possible run over the last highs at 7.30
0 · Reply
Investor1337
Investor1337 Jul. 8 at 8:33 PM
$GLTO please wake its been 5 years……
0 · Reply
MadMusk
MadMusk Jul. 7 at 4:00 PM
$CLOV happy Oster of 1000 shares. $GLTO
0 · Reply
signaljumper
signaljumper Jun. 27 at 1:55 PM
$GLTO looking for break of 4$ in the next 2 weeks
0 · Reply
signaljumper
signaljumper Jun. 26 at 4:01 PM
$GLTO time will buyout on this stock
0 · Reply
US_Bull
US_Bull Jun. 23 at 11:04 AM
$GLTO Options given 3 days ago with exercise price of 3.22$ they must feel pretty confident that SP will keep rising or else they would have issued those options at a lower exercise price. https://galecto.gcs-web.com/static-files/0fcbc34a-8b86-481c-a71d-5ef8ebf6d25c
0 · Reply
Kilarck
Kilarck Jun. 22 at 5:19 PM
$GLTO https://talkmarkets.com/content/stocks--equities/galectin-therapeutics-is-undervalued-and-with-short-squeeze-underway?post=504960 Short squeeze on another Galectin inhibitor underway!!!
0 · Reply
US_Bull
US_Bull Jun. 20 at 7:54 PM
$GLTO Slowly but surely rising I prefer it that way when it is under the radar of retail until they dropped the PR to start the rocket launch.
0 · Reply
Latest News on GLTO
Galecto Reports First Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 2 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Galecto Reports Full-Year 2024 Financial Results

Mar 19, 2025, 4:45 PM EDT - 4 months ago

Galecto Reports Full-Year 2024 Financial Results

Galecto to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 6 months ago

Galecto to Participate in Upcoming Investor Conferences

Galecto Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:30 AM EDT - 9 months ago

Galecto Reports Third Quarter 2024 Financial Results

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 15, 2024, 8:30 AM EDT - 10 months ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Oct 7, 2024, 8:45 AM EDT - 10 months ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Galecto Announces Reverse Stock Split

Aug 28, 2024, 9:00 AM EDT - 11 months ago

Galecto Announces Reverse Stock Split

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Dec 21, 2023, 4:05 PM EST - 1 year ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Galecto Announces Plans to Explore Strategic Alternatives

Sep 26, 2023, 4:01 PM EDT - 1 year ago

Galecto Announces Plans to Explore Strategic Alternatives

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Galecto to Present at Investor Conferences in September

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Galecto Reports Second Quarter Operating and Financial Results

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Galecto Set to Join Russell Microcap® Index

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

Galecto to Present Poster at Upcoming ATS 2023 International Conference

May 17, 2023, 4:01 PM EDT - 2 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Galecto Reports First Quarter Operating and Financial Results

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Galecto Reports First Quarter Operating and Financial Results

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 18, 2023, 7:01 PM EDT - 2 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Galecto to Present Two Posters at AACR Annual Meeting 2023

Apr 13, 2023, 8:30 AM EDT - 2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 9, 2023, 7:00 AM EST - 2 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Mar 2, 2023, 4:05 PM EST - 2 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Galecto to Participate in SVB Securities Global Biopharma Conference

Feb 1, 2023, 8:00 AM EST - 2 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Dec 7, 2022, 4:05 PM EST - 2 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 9:15 AM EST - 2 years ago

Galecto Reports Third Quarter Operating and Financial Results

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 8, 2022, 6:00 AM EST - 2 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Galecto to Participate in Jefferies London Healthcare Conference

Nov 3, 2022, 8:00 AM EDT - 2 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 31, 2022, 8:00 AM EDT - 2 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Galecto to Participate at Jefferies Healthcare Conference

May 31, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at Jefferies Healthcare Conference

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

May 26, 2022, 8:30 AM EDT - 3 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Mar 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto Reports Financial Results for the Year Ended December 31, 2021

Feb 17, 2022, 5:00 PM EST - 3 years ago

Galecto Reports Financial Results for the Year Ended December 31, 2021

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Jan 27, 2022, 7:00 AM EST - 3 years ago

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

Dec 13, 2021, 8:00 AM EST - 3 years ago

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

Nov 2, 2021, 11:26 AM EDT - 4 years ago

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Nov 2, 2021, 8:00 AM EDT - 4 years ago

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Galecto to Present at Upcoming Investor Conferences

Oct 26, 2021, 8:00 AM EDT - 4 years ago

Galecto to Present at Upcoming Investor Conferences

Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

Sep 15, 2021, 8:30 AM EDT - 4 years ago

Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Sep 13, 2021, 8:00 AM EDT - 4 years ago

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

MadMusk
MadMusk Jul. 25 at 9:37 AM
$OKLO I got 1000€ on the Short Side . Now can Oberlap loses on $OPTT . $GLTO
0 · Reply
Investor1337
Investor1337 Jul. 21 at 4:17 PM
$GLTO Realistic timeframe for topline results is Q3–Q4 2025, likely aligned with the major oncology conferences Next: BO / partner / RS? (as an investor I would like ceo to be more in contact with investors)
0 · Reply
signaljumper
signaljumper Jul. 14 at 9:55 PM
$GLTO teady for 4$++ If we get some more volume than stocj could possible run over the last highs at 7.30
0 · Reply
Investor1337
Investor1337 Jul. 8 at 8:33 PM
$GLTO please wake its been 5 years……
0 · Reply
MadMusk
MadMusk Jul. 7 at 4:00 PM
$CLOV happy Oster of 1000 shares. $GLTO
0 · Reply
signaljumper
signaljumper Jun. 27 at 1:55 PM
$GLTO looking for break of 4$ in the next 2 weeks
0 · Reply
signaljumper
signaljumper Jun. 26 at 4:01 PM
$GLTO time will buyout on this stock
0 · Reply
US_Bull
US_Bull Jun. 23 at 11:04 AM
$GLTO Options given 3 days ago with exercise price of 3.22$ they must feel pretty confident that SP will keep rising or else they would have issued those options at a lower exercise price. https://galecto.gcs-web.com/static-files/0fcbc34a-8b86-481c-a71d-5ef8ebf6d25c
0 · Reply
Kilarck
Kilarck Jun. 22 at 5:19 PM
$GLTO https://talkmarkets.com/content/stocks--equities/galectin-therapeutics-is-undervalued-and-with-short-squeeze-underway?post=504960 Short squeeze on another Galectin inhibitor underway!!!
0 · Reply
US_Bull
US_Bull Jun. 20 at 7:54 PM
$GLTO Slowly but surely rising I prefer it that way when it is under the radar of retail until they dropped the PR to start the rocket launch.
0 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 20 at 7:24 PM
$GLTO giddyup dammit! 😂
0 · Reply
joe77w
joe77w Jun. 20 at 1:25 PM
$GLTO 13 mln in net equity and 1.3 mln os does mean 10 usd per share, two promising compounds, significantly cheap and undervalued https://www.otcmarkets.com/filing/html?id=18446825&guid=G4i-k67MdXvnJth
0 · Reply
US_Bull
US_Bull Jun. 20 at 12:01 PM
$GLTO Here we go!!!
0 · Reply
US_Bull
US_Bull Jun. 20 at 11:09 AM
$GLTO Loaded more pre-market.
0 · Reply
US_Bull
US_Bull Jun. 20 at 1:36 AM
$GLTO I agree any day now this one rockets straight up part of the downpour has also been weak bio sector selloff for past few months. Microfloat can make this rocket out of the blue sympathy play let alone any hint of positive pr. I see double digits in few weeks.
0 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 19 at 10:26 PM
$GLTO all the excitement over GALT is about to trigger an avalanche over here! After listening to GALTs KOL I think belapectin is approvable. FOMO traders will be looking for other galectin biology plays and GLTO is it. Selvigaltin is further away in liver disease but closer for cancer. Traders will go nuts when they realize GLTO float is only 1M shares and MC just $4M. The fact that selvigaltin is also oral makes this even more appealing. GALT is developing an oral version of belapectin but is still pre clinical and will have to run additional trials including P3 for the oral version. It’s about to get exciting over here and it’s about time!
0 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 19 at 6:03 PM
$GLTO 👀 good news for $GALT is going to spill over to GLTO. GALT leads in liver disease while GLTO leads in cancer. My sense is Merck is lurking since they’re supplying Keytruda for the IIT P2 trial in MM & HNSCS. Early look coming any time. I believe Galecto plans to offload Selvigaltin (GB1211) to Merck with large payment and CVRs to progress GB3226 in AML. That’s why Galecto didn’t do a PIPE at favorable pricing with their SA and why they’ve essentially been dark. More good news and for GALT will put more eyes on GLTO. With only 1M share float it won’t take much to send this 😉
3 · Reply
US_Bull
US_Bull Jun. 19 at 2:46 PM
$GLTO Low float dangerous cocktail for shorts any news they PR this is flying hard getting the tail wind from a pathetically low market cap compared to other Gal-3 inh plays, the fact that it is ultra low-float, and the Danish parlament cutting the phantom tax.
1 · Reply
US_Bull
US_Bull Jun. 19 at 1:59 PM
$GLTO Just recently the 'phantom tax' in Denmark has been abolished that should further boost the company significantly just makes this company a greater buy now. "When passed, the new law will allow founders to defer taxes on proceeds from company sales that depend on future milestone payments — only paying tax if and when those payments actually arrive." Probably why the chart has turned bullish North again.
1 · Reply
US_Bull
US_Bull Jun. 19 at 10:04 AM
$GLTO Finally chart looks extremely bullish could get a sympathy push from GALT run since they both basically target Gal-3 and are polysaccharide molecules.
0 · Reply
US_Bull
US_Bull Jun. 19 at 10:03 AM
$GLTO Lol they have a market cap of about 4.4 million and they have 11 million in the bank with no debt 4 drugs in the pipeline for cancer and NASH cirrh. what am I missing here lol. Next huge gem runner. And they are supported by Novo Nordic seed.
0 · Reply